Joy M Schmitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4100891/publications.pdf

Version: 2024-02-01

154	7,570	40	82
papers	citations	h-index	g-index
156	156	156	6527 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Electrophysiological responses to emotional and cocaine cues reveal individual neuroaffective profiles in cocaine users Experimental and Clinical Psychopharmacology, 2022, 30, 514-524.	1.3	8
2	Nonjudgmental acceptance: Associations with substance-related cue reactivity in adults with substance use disorders and posttraumatic stress. Addictive Behaviors, 2022, 126, 107211.	1.7	1
3	Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 115, 110506.	2.5	2
4	Distress tolerance: prospective associations with cognitive-behavioral therapy outcomes in adults with posttraumatic stress and substance use disorders. Cognitive Behaviour Therapy, 2022, 51, 326-342.	1.9	7
5	The potential of brain stimulation techniques for substance use disorder treatment. Revista Brasileira De Psiquiatria, 2022, , .	0.9	1
6	Early pain, stress, and opioid use following traumatic injury. Journal of Opioid Management, 2022, 18, 17-25.	0.2	1
7	A metaâ€nnalysis of tractâ€based spatial statistics studies examining white matter integrity in cocaine use disorder. Addiction Biology, 2021, 26, e12902.	1.4	20
8	Plasma pro- and anti-inflammatory cytokines may relate to cocaine use, cognitive functioning, and depressive symptoms in cocaine use disorder. American Journal of Drug and Alcohol Abuse, 2021, 47, 52-64.	1.1	10
9	Objective analysis of language use in cognitive-behavioral therapy: associations with symptom change in adults with co-occurring substance use disorders and posttraumatic stress. Cognitive Behaviour Therapy, 2021, 50, 89-103.	1.9	5
10	Bupropion and Naltrexone in Methamphetamine Use Disorder. New England Journal of Medicine, 2021, 384, 140-153.	13.9	139
11	Cocaine-specific speed-accuracy trade-off during anti-saccade testing differentiates patients with cocaine use disorder who achieve initial abstinence during treatment. Journal of Psychopharmacology, 2021, 35, 611-614.	2.0	3
12	White matter deficits in cocaine use disorder: convergent evidence from in vivo diffusion tensor imaging and ex vivo proteomic analysis. Translational Psychiatry, 2021, 11, 252.	2.4	12
13	Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine and Tobacco Research, 2021, 23, 1682-1690.	1.4	21
14	The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: A bayesian mediation analysis. Drug and Alcohol Dependence, 2021, 225, 108800.	1.6	3
15	Decreased cocaine demand following contingency management treatment. Drug and Alcohol Dependence, 2021, 226, 108883.	1.6	10
16	Prevalence and Correlates of Sex Selling and Sex Purchasing among Adults Seeking Treatment for Cocaine Use Disorder. Substance Use and Misuse, 2021, 56, 1-13.	0.7	1
17	Posttraumatic stress symptom clusters differentially predict late positive potential to cocaine imagery cues in trauma-exposed adults with cocaine use disorder. Drug and Alcohol Dependence, 2021, 227, 108929.	1.6	3
18	Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug and Alcohol Dependence, 2021, 228, 109054.	1.6	7

#	Article	IF	CITATIONS
19	Initial development of a brief assessment of cocaine demand. Behavioural Pharmacology, 2021, 32, 351-355.	0.8	1
20	Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial. Contemporary Clinical Trials, 2021, 111, 106603.	0.8	0
21	Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Research, 2020, 1731, 146359.	1.1	33
22	Association Between Recent Cannabis Consumption and Withdrawal-Related Symptoms During Early Abstinence Among Females With Smoked Cocaine Use Disorder. Journal of Addiction Medicine, 2020, 14, e37-e43.	1.4	4
23	Mindfulness as a predictor of cognitive-behavioral therapy outcomes in inner-city adults with posttraumatic stress and substance dependence. Addictive Behaviors, 2020, 104, 106283.	1.7	8
24	Baseline cocaine demand predicts contingency management treatment outcomes for cocaine-use disorder Psychology of Addictive Behaviors, 2020, 34, 164-174.	1.4	14
25	Elevated Neutrophil to Lymphocyte Ratio in Older Adults with Cocaine Use Disorder as a Marker of Chronic Inflammation. Clinical Psychopharmacology and Neuroscience, 2020, 18, 32-40.	0.9	21
26	A Novel, Integrated Cognitive-Behavioral Therapy for Co-Occurring Posttraumatic Stress and Substance Use Disorders: A Case Study. Cognitive and Behavioral Practice, 2019, 26, 307-322.	0.9	12
27	Measures of possible allostatic load in comorbid cocaine and alcohol use disorder: Brain white matter integrity, telomere length, and anti-saccade performance. PLoS ONE, 2019, 14, e0199729.	1.1	17
28	Regional differences in white matter integrity in stimulant use disorders: A meta-analysis of diffusion tensor imaging studies. Drug and Alcohol Dependence, 2019, 201, 29-37.	1.6	27
29	Baseline resting heart rate variability predicts postâ€traumatic stress disorder treatment outcomes in adults with coâ€occurring substance use disorders and postâ€traumatic stress. Psychophysiology, 2019, 56, e13377.	1.2	23
30	Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. Diabetes Research and Clinical Practice, 2019, 149, 78-88.	1.1	7
31	Resting Heart Rate Variability: Exploring Associations With Symptom Severity in Adults With Substance Use Disorders and Posttraumatic Stress. Journal of Dual Diagnosis, 2019, 15, 2-7.	0.7	13
32	Using a data science approach to predict cocaine use frequency from depressive symptoms. Drug and Alcohol Dependence, 2019, 194, 310-317.	1.6	4
33	A sequential multiple assignment randomized trial for cocaine cessation and relapse prevention: Tailoring treatment to the individual. Contemporary Clinical Trials, 2018, 65, 109-115.	0.8	19
34	Development of a novel, integrated cognitive-behavioral therapy for co-occurring posttraumatic stress and substance use disorders: A pilot randomized clinical trial. Contemporary Clinical Trials, 2018, 65, 123-129.	0.8	21
35	Altered anterior cingulate cortex to hippocampus effective connectivity in response to drug cues in men with cocaine use disorder. Psychiatry Research - Neuroimaging, 2018, 271, 59-66.	0.9	17
36	Anhedonia in cocaine use disorder is associated with inflammatory gene expression. PLoS ONE, 2018, 13, e0207231.	1.1	12

#	Article	IF	CITATIONS
37	Distress tolerance: Associations with trauma and substance cue reactivity in low-income, inner-city adults with substance use disorders and posttraumatic stress Psychology of Addictive Behaviors, 2018, 32, 264-276.	1.4	22
38	A preliminary longitudinal study of white matter alteration in cocaine use disorder subjects. Drug and Alcohol Dependence, 2017, 173, 39-46.	1.6	18
39	PPARâ€gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a doubleâ€blind randomized controlled pilot trial. Addiction, 2017, 112, 1861-1868.	1.7	58
40	Cognitive-behavioral therapies for depression and substance use disorders: An overview of traditional, third-wave, and transdiagnostic approaches. American Journal of Drug and Alcohol Abuse, 2017, 43, 402-415.	1.1	57
41	Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder. Journal of Substance Abuse Treatment, 2017, 72, 32-39.	1.5	69
42	Bupropion and naltrexone for smoking cessation: A doubleâ€blind randomized placeboâ€controlled clinical trial. Clinical Pharmacology and Therapeutics, 2016, 100, 344-352.	2.3	21
43	Distress Tolerance. Behavior Modification, 2016, 40, 120-143.	1.1	40
44	Bradycardia as a Marker of Chronic Cocaine Use: A Novel Cardiovascular Finding. Behavioral Medicine, 2016, 42, 1-8.	1.0	14
45	The role of avoidance and inflexibility in characterizing response to contingency management for cocaine use disorders: A secondary profile analysis Psychology of Addictive Behaviors, 2015, 29, 408-413.	1.4	13
46	Serotonin transporter gene promoter polymorphism predicts relationship between years of cocaine use and impulsivity. Psychiatric Genetics, 2015, 25, 213-214.	0.6	4
47	Demographic and Psychological Factors Associated With Lifetime Cocaine Use. Addictive Disorders and Their Treatment, 2015, 14, 70-77.	0.5	7
48	Effects of oxytocin on aggressive responding in healthy adult men. Behavioural Pharmacology, 2015, 26, 798-804.	0.8	28
49	A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. American Journal of Psychiatry, 2015, 172, 1014-1021.	4.0	30
50	Neural correlates of impulsive aggressive behavior in subjects with a history of alcohol dependence Behavioral Neuroscience, 2015, 129, 183-196.	0.6	37
51	Anti-saccade error rates as a measure of attentional bias in cocaine dependent subjects. Behavioural Brain Research, 2015, 292, 493-499.	1.2	23
52	Hospital Length of Stay in Individuals With Schizophrenia With and Without Cocaine-Positive Urine Drug Screens at Hospital Admission. Journal of Nervous and Mental Disease, 2015, 203, 33-36.	0.5	5
53	Prevalence of traumatic brain injury in cocaine-dependent research volunteers. American Journal on Addictions, 2015, 24, 341-347.	1.3	17
54	Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine. Journal of Addiction Research & Therapy, 2014, 05, 176.	0.2	11

#	Article	IF	CITATIONS
55	Biomarkers for the Development of New Medications for Cocaine Dependence. Neuropsychopharmacology, 2014, 39, 202-219.	2.8	34
56	The influence of dopamine \hat{l}^2 -hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence. Pharmacogenetics and Genomics, 2014, 24, 370-373.	0.7	16
57	Using prize-based incentives to enhance daily interactive voice response (IVR) compliance: A feasibility study. Journal of Substance Abuse Treatment, 2014, 46, 74-77.	1.5	16
58	A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: Modafinil, levodopa–carbidopa, naltrexone. Drug and Alcohol Dependence, 2014, 136, 100-107.	1.6	48
59	Baby's Breath II protocol development and design: A secondhand smoke exposure prevention program targeting infants discharged from a neonatal intensive care unit. Contemporary Clinical Trials, 2013, 35, 97-105.	0.8	17
60	Stress and Length of Stay in Therapeutic Community Treatment for Adolescents With Substance Use Disorders. Addictive Disorders and Their Treatment, 2013, 12, 175-182.	0.5	6
61	Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects. Journal of Psychopharmacology, 2013, 27, 801-807.	2.0	10
62	Behavioral Activation and Inhibition, Negative Affect, and Gambling Severity in a Sample of Young Adult College Students. Journal of Gambling Studies, 2012, 28, 437-449.	1.1	39
63	Increased intra-individual reaction time variability in cocaine-dependent subjects: Role of cocaine-related cues. Addictive Behaviors, 2012, 37, 193-197.	1.7	20
64	A Stage I pilot study of acceptance and commitment therapy for methadone detoxification. Drug and Alcohol Dependence, 2012, 125, 215-222.	1.6	64
65	Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A2A Antagonist in Cocaine Dependent Subjects. Frontiers in Psychiatry, 2012, 3, 44.	1.3	21
66	Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation. Frontiers in Psychiatry, 2012, 3, 77.	1.3	53
67	The Influence of Baseline Marijuana Use on Treatment of Cocaine Dependence: Application of an Informative-Priors Bayesian Approach. Frontiers in Psychiatry, 2012, 3, 92.	1.3	6
68	Relationship between attentional bias to cocaine-related stimuli and impulsivity in cocaine-dependent subjects. American Journal of Drug and Alcohol Abuse, 2011, 37, 117-122.	1.1	69
69	Contingency management and levodopa-carbidopa for cocaine treatment: A comparison of three behavioral targets Experimental and Clinical Psychopharmacology, 2010, 18, 238-244.	1.3	29
70	Working memory fMRI activation in cocaine-dependent subjects: Association with treatment response. Psychiatry Research - Neuroimaging, 2010, 181, 174-182.	0.9	86
71	Relationship between impulsivity and decision making in cocaine dependence. Psychiatry Research, 2010, 178, 299-304.	1.7	94
72	Substance Abuser Impulsivity Decreases with a Nine-Month Stay in a Therapeutic Community. American Journal of Drug and Alcohol Abuse, 2009, 35, 417-420.	1.1	19

#	Article	lF	CITATIONS
73	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Pilot Study of Naltrexone in Outpatients With Bipolar Disorder and Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2009, 33, 1863-1869.	1.4	83
74	Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 2009, 101, 34-41.	1.6	112
75	Baseline Neurocognitive Profiles Differentiate Abstainers and Non-Abstainers in a Cocaine Clinical Trial. Journal of Addictive Diseases, 2009, 28, 250-257.	0.8	35
76	Cocaine Dependence and Concurrent Marijuana Use: A Comparison of Clinical Characteristics. American Journal of Drug and Alcohol Abuse, 2009, 35, 193-198.	1.1	32
77	Mindfulness-Based Stress Reduction in Therapeutic Community Treatment: A Stage 1 Trial. American Journal of Drug and Alcohol Abuse, 2009, 35, 103-108.	1.1	35
78	Evaluation of Heterogeneity in Pharmacotherapy Trials for Drug Dependence: A Bayesian Approach. American Journal of Drug and Alcohol Abuse, 2009, 35, 95-102.	1.1	20
79	Comparison of 3 L-α-acetyl-methadol (LAAM) Maintenance Strategies for Heroin Dependence. Addictive Disorders and Their Treatment, 2009, 8, 191-200.	0.5	1
80	Factor Analyses of the Allen Barriers to Treatment Instrument in a Sample of Women Seeking Outpatient Treatment for Substance Abuse. Addictive Disorders and Their Treatment, 2009, 8, 185-190.	0.5	2
81	High-Dose Naltrexone Therapy for Cocaine-Alcohol Dependence. American Journal on Addictions, 2009, 18, 356-362.	1.3	36
82	Testing the Significance of Difference in Average Rates of Change in Controlled Longitudinal Studies With High Dropout Rates. Methodology, 2009, 5, 46-54.	0.5	1
83	Use of stimulants to treat cocaine and methamphetamine abuse. Current Psychiatry Reports, 2008, 10, 385-391.	2.1	22
84	Factor structure and diagnostic efficiency of the BDI-II in treatment-seeking substance users. Drug and Alcohol Dependence, 2008, 93, 271-278.	1.6	32
85	Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. Drug and Alcohol Dependence, 2008, 94, 142-150.	1.6	112
86	Drug Preference in Cocaine and Alcohol Dual-Dependent Patients. American Journal of Drug and Alcohol Abuse, 2008, 34, 211-217.	1.1	5
87	Citalopram Combined with Behavioral Therapy Reduces Cocaine Use: A Double-Blind, Placebo-Controlled Trial. American Journal of Drug and Alcohol Abuse, 2007, 33, 367-378.	1.1	92
88	Bupropion and cognitive-behavioral therapy for smoking cessation in women. Nicotine and Tobacco Research, 2007, 9, 699-709.	1.4	35
89	Behavioral Therapies Trials. Nursing Research, 2007, 56, 210-216.	0.8	14
90	Moderators of delay tolerance in treatment-seeking cocaine users. Addictive Behaviors, 2007, 32, 370-376.	1.7	12

#	Article	IF	CITATIONS
91	Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: A replication and extension study. Addictive Behaviors, 2007, 32, 875-880.	1.7	33
92	Illusory predictors: Generalizability of findings in cocaine treatment retention research. Addictive Behaviors, 2007, 32, 2819-2836.	1.7	11
93	Safety, tolerability and efficacy of levodopa–carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. Drug and Alcohol Dependence, 2007, 88, 214-223.	1.6	40
94	The role of drug use outcome expectancies in substance abuse risk: An interactional–transformational model. Addictive Behaviors, 2006, 31, 2038-2062.	1.7	64
95	The role of homework in cognitive-behavioral therapy for cocaine dependence Journal of Consulting and Clinical Psychology, 2006, 74, 633-637.	1.6	62
96	Using Addiction Severity Profiles to Differentiate Cocaine-Dependent Patients with and without Comorbid Major Depression. American Journal on Addictions, 2006, 15, 362-369.	1.3	22
97	Increasing Knowledge of HIV and Hepatitis C During Substance Abuse Treatment. Addictive Disorders and Their Treatment, 2005, 4, 71-76.	0.5	5
98	Medication Compliance During a Smoking Cessation Clinical Trial: A Brief Intervention Using MEMS Feedback. Journal of Behavioral Medicine, 2005, 28, 139-147.	1.1	48
99	Agonist-Like or Antagonist-Like Treatment for Cocaine Dependence with Methadone for Heroin Dependence: Two Double-Blind Randomized Clinical Trials. Neuropsychopharmacology, 2004, 29, 969-981.	2.8	174
100	Treatment of Cocaine–Alcohol Dependence with Naltrexone and Relapse Prevention Therapy. American Journal on Addictions, 2004, 13, 333-341.	1.3	48
101	"Who gets in?― Recruitment and screening processes of outpatient substance abuse trials. Addictive Behaviors, 2004, 29, 389-398.	1.7	14
102	Impact of a motivational intervention on mechanisms of change in low-income pregnant smokers. Addictive Behaviors, 2004, 29, 1649-1657.	1.7	41
103	Comparing Measures of Medication Taking in a Pharmacotherapy Trial for Cocaine Dependence. Addictive Disorders and Their Treatment, 2004, 3, 165-173.	0.5	15
104	Treatment of Nicotine Addiction. Addictive Disorders and Their Treatment, 2004, 3, 97-109.	0.5	0
105	Hepatitis C Knowledge Assessment and Counseling Within the Context of Substance Abuse Treatment. Addictive Disorders and Their Treatment, 2004, 3, 18-26.	0.5	5
106	Concurrent treatment for alcohol and tobacco dependence: are patients ready to quit both?. Drug and Alcohol Dependence, 2003, 69, 1-7.	1.6	35
107	Assessment of the relative reinforcement value of smoking and drinking using a multiple-choice measurement strategy. Nicotine and Tobacco Research, 2003, 5, 729-734.	1.4	13
108	Tobacco, alcohol and caffeine use in a low-income, pregnant population. Journal of Obstetrics and Gynaecology, 2003, 23, 247-251.	0.4	11

#	Article	IF	CITATIONS
109	Stress and Behavior Change in a Substance-Abusing Population Following September 11, 2001. Addictive Disorders and Their Treatment, 2003, 2, 59-61.	0.5	2
110	Smoking Cessation in Women with Cardiac Risk. American Journal of the Medical Sciences, 2003, 326, 192-196.	0.4	9
111	Cognitive–Behavioral Treatment of Bipolar Disorder and Substance Abuse: A Preliminary Randomized Study. Addictive Disorders and Their Treatment, 2002, 1, 17-24.	0.5	66
112	Determining predictors of attrition in an outpatient substance abuse program. American Journal of Drug and Alcohol Abuse, 2002, 28, 55-72.	1.1	83
113	Psychiatric Aspects of Impulsivity. American Journal of Psychiatry, 2001, 158, 1783-1793.	4.0	2,060
114	Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addictive Behaviors, 2001, 26, 167-180.	1.7	153
115	Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug and Alcohol Dependence, 2001, 63, 207-214.	1.6	104
116	The impact of impulsivity on cocaine use and retention in treatment. Journal of Substance Abuse Treatment, 2001, 21, 193-198.	1.5	374
117	Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial. Journal of Clinical Psychopharmacology, 2001, 21, 522-526.	0.7	223
118	Motivational interviewing with cocaine-dependent patients: A pilot study Journal of Consulting and Clinical Psychology, 2001, 69, 858-862.	1.6	144
119	Cocaine dependence with and without comorbid depression: a comparison of patient characteristics. Drug and Alcohol Dependence, 2000, 60, 189-198.	1.6	42
120	Laboratory Measures of Methylphenidate Effects in Cocaine-Dependent Patients Receiving Treatment. Journal of Clinical Psychopharmacology, 2000, 20, 61-68.	0.7	34
121	Risperidone for the Treatment of Cocaine Dependence: Randomized, Double-Blind Trial. Journal of Clinical Psychopharmacology, 2000, 20, 305-310.	0.7	108
122	Smoking cessation in women with cardiac risk: A comparative study of two theoretically based therapies. Nicotine and Tobacco Research, 1999, 1, 87-94.	1.4	40
123	Use of Monetary Reinforcers by Cocaine-Dependent Outpatients. Journal of Substance Abuse Treatment, 1999, 17, 229-236.	1.5	13
124	Behavioral and Emotional Problems Among Children of Cocaine―and Opiateâ€Dependent Parents. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 421-428.	0.3	88
125	Cocaine craving: An evaluation across treatment phases. Journal of Substance Abuse, 1998, 10, 9-17.	1.1	44
126	Effects of nicotine on methadone self-administration in humans. Drug and Alcohol Dependence, 1998, 50, 157-165.	1.6	61

#	Article	IF	CITATIONS
127	Cue reactivity in cocaine-dependent subjects: effects of cue type and cue modality. Addictive Behaviors, 1998, 23, 7-15.	1.7	56
128	Context modulated effects of nicotine abstinence on human cooperative responding. Experimental and Clinical Psychopharmacology, 1998, 6, 390-398.	1.3	2
129	Medication take-home doses and contingency management Experimental and Clinical Psychopharmacology, 1998, 6, 162-168.	1.3	36
130	Psychologic treatment of substance abuse. Current Opinion in Psychiatry, 1998, 11, 289-293.	3.1	0
131	Ritanserin in the treatment of cocaine dependence. Biological Psychiatry, 1997, 42, 932-940.	0.7	22
132	Relapse prevention treatment for cocaine dependence: Group vs. individual format. Addictive Behaviors, 1997, 22, 405-418.	1.7	42
133	Treatment outcome of cocaine-alcohol dependent patients. Drug and Alcohol Dependence, 1997, 47, 55-61.	1.6	43
134	Replacement Medication for Cocaine Dependence. Journal of Clinical Psychopharmacology, 1997, 17, 485-488.	0.7	170
135	Assessing the validity of nicotine abstinence effects by self- and observer ratings under "blinded" conditions Experimental and Clinical Psychopharmacology, 1996, 4, 330-335.	1.3	6
136	War-Related Changes in Cigarette Smoking: A Survey Study of Health Professionals in Sarajevo. Substance Use and Misuse, 1996, 31, 639-646.	0.7	18
137	Situational analysis of coping in substance-abusing patients. Journal of Substance Abuse, 1995, 7, 189-204.	1.1	4
138	Contingent reinforcement for reduced carbon monoxide levels in methadone maintenance patients. Addictive Behaviors, 1995, 20, 171-179.	1.7	30
139	Behavioral treatment of cocaine-dependent pregnant women and TB-exposed patients. Addictive Behaviors, 1995, 20, 533-542.	1.7	41
140	Fluoxetine Is Ineffective for Treatment of Cocaine Dependence or Concurrent Opiate and Cocaine Dependence. Journal of Clinical Psychopharmacology, 1995, 15, 163-174.	0.7	148
141	Treatment session frequency and smoking cessation. Journal of Substance Abuse, 1994, 6, 77-85.	1.1	8
142	Cessation of cocaine use during pregnancy: A preliminary comparison. Addictive Behaviors, 1994, 19, 697-702.	1.7	11
143	A Survey of Posthospitalization Treatment Needs and Preferences in Cocaine Abusers. American Journal on Addictions, 1994, 3, 227-235.	1.3	5
144	A menu of potential reinforcers in a methadone maintenance program. Journal of Substance Abuse Treatment, 1994, 11, 425-431.	1.5	16

#	Article	IF	CITATIONS
145	Dr. Elk and colleagues' response. Journal of Substance Abuse Treatment, 1994, 11, 61-62.	1.5	О
146	The effects of high and low doses of methadone on cigarette smoking. Drug and Alcohol Dependence, 1994, 34, 237-242.	1.6	70
147	Experimental analysis of the role of expectancy in nicotine withdrawal Psychology of Addictive Behaviors, 1994, 8, 169-178.	1.4	24
148	Compliance with tubercolosis treatment in methadone-maintained patients: Behavioral interventions. Journal of Substance Abuse Treatment, 1993, 10, 371-382.	1.5	26
149	A proposed revision of the fagerstrom tolerance questionnaire. Addictive Behaviors, 1993, 18, 135-143.	1.7	60
150	Cognitive and affective responses to successful coping during smoking cessation. Journal of Substance Abuse, 1993, 5, 61-72.	1.1	21
151	Discriminative utility of a brief cognitive status assessment with alcoholics and the impact of cognitive status on acquisition of treatment-relevant information Psychology of Addictive Behaviors, 1992, 6, 34-40.	1.4	15
152	A critical review of the reasons for smoking scale. Journal of Substance Abuse, 1991, 3, 441-455.	1.1	34
153	A fine-grained analysis of the role of self-efficacy in self-initiated attempts to quit smoking Journal of Consulting and Clinical Psychology, 1990, 58, 317-322.	1.6	59
154	Trauma and Emotion Regulation: Associations with Depressive Symptoms and Cocaine Use among Treatment-seeking Adults. International Journal of Mental Health and Addiction, $0, 1$.	4.4	0